drugset / Trial / NCT00599001

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

NCT00599001

Phase 1 Completed 26 enrolled Dynavax Technologies Corporation
RandomizedParallel-groupSingle-blindTreatment

Summary

The main purpose of this study is to assess the safety, tolerability, and biological activity of SD-101 compared with placebo in healthy male volunteers.

Timeline

Start
2008-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelitolimod Oligonucleotide (other) Subcutaneous

Indications

No indication recorded.